Phillip Yates joins the Houston Innovators Podcast to discuss two initiatives he's launching to support diverse founders in Houston. Photo courtesy of Equiliberty

Phillip Yates is juggling a lot. The Houston lawyer started Equiliberty, a technology company that's part financial resource and part social network, to help diverse communities create lasting wealth. Now, he's also launching Diversity Fund Houston — a $3 million initiative to support diverse tech founders — ahead of the inaugural Black Entrepreneurship Week, which Yates is hosting in Houston starting Saturday, November 27.

While it is a handful, all three initiatives align with Yates's goal to move the needle on improving equity when it comes to access to capital, finding a community, and creating institutional change. Just like most Black professional, he's faced his share of challenges — but he's persevered thanks to his mentors, family, and supportive network.

"Everytime I failed, there was somebody there that made sure I stayed on track," Yates shares on the Houston Innovators Podcast.

Now Yates, across his efforts, wants to help create this same type of support for others. Equaliberty connects users to a hyper-local network and mentor, as well as relationships to financial institutions and key resources.

"We're doing two things — we're creating a new asset class for banks and financial institutions, but then also we're building a group of wealth creators in the community who will take ownership in the geographical region they live in, which isn't happening," Yates says. "We throw the word 'gentrification' around, but we never attack it at the root problem, and a lot of times it's ownership."

Ultimately, Yates says he wants to help to move the needle on eliminating poverty in the United States — it's not going to happen overnight or with him alone. One huge step toward this goal is raising awareness of the issues, and that's what he hopes to do with Black Entrepreneurship Week.

BEW will feature several opportunities — from the Black Market, which will allow people to shop local Black merchants, to a special Giving Tuesday event to support Black-focused nonprofits in Houston. Specifically, Yates wants to target a multi-generational crowd — that's what's goring to drive lasting changes.

"When you have a wealth initiative, you can't just talk to the parents or the youth — you're still going to have a missing link there," Yates says on the show, explaining the week's wealth challenge that will reinforce this idea.

Access to wealth is a key focus for Yates, who announced the launch of Diversity Fund Houston this week co-founded by emerging fund managers Tiffany Williams, Kiley Summers, and Yates and in partnership with Bank of America, Houston Area Urban League, Hello Alice, Impact Hub Houston, Equiliberty, DivInc., and Prairie View A&M University.

The fund will target early-stage companies founded by diverse entrepreneurs — tapping into an underserved community, not just because it's the right thing to do but because there are real opportunities. And now is the time to make these changes, Yates says.

"The Black American community is at a point where millennials are coming into their own," Yates says explaining how he's at the opportune point in his life. "I'm stable enough and still young enough where I can make these contributions — and the same thing with my co-founders. ... Time is of the essence for our community."

Yates shares more on what to expect at BEW and with the new fund on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”